vimarsana.com

Latest Breaking News On - Health canada interim order respecting the importation - Page 2 : vimarsana.com

2nd COVID vaccine approved for use in Canada

2nd COVID vaccine approved for use in Canada
napaneetoday.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from napaneetoday.ca Daily Mail and Mail on Sunday newspapers.

Dr Reddy s files application for Reeqonus tablets to treat COVID-19 in Canada

Dr. Reddy’s files application for Reeqonus tablets to treat COVID-19 in Canada Dr. Reddy’s, alongside Global Response Aid and Appili Therapeutics, has filed an application on behalf of Reeqonus (favipiravir) tablets in Canada. “Our outreach to Canada is a part of our global efforts to play an active role in addressing the COVID-19 situation, said Mitch Wilson, CEO of GRA.  The filing is a testimony to our commitment of bringing a potential solution to COVID-19 for the Canadian population.” The companies have filed a motion for the tablets to be used for the acute treatment of mild to moderate COVID-19 in adult patients under Health Canada’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19.

Dr Reddy s seeks nod from Canada for Favipiravir pills for Covid treatment

Dr Reddy s Laboratories Ltd, Appili Therapeutics and Global Response Aid FZCO (GRA) on Tuesday announced that Dr Reddy s Canada has filed an application on behalf of the consortium for Reeqonus (favipiravir) tablets for acute treatment of mild to moderate COVID-19 adult patients. The application has been filed under Health Canada s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19, Hyderabad-headquartered pharma major Dr Reddy s said in a statement. In September, the interim order was signed by Canada s Minister of Health to create a new authorisation pathway that will help expedite the authorisation of drugs and vaccines for COVID-19.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.